X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Vetter wins Axia Best Managed Company Award

Content Team by Content Team
5th June 2020
in News
Vetter wins Axia Best Managed Company Award

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Vetter has been awarded the Axia Best Managed Companies Award for its outstanding corporate management. The coveted seal of approval is awarded once a year by the consulting firm Deloitte, WirtschaftsWoche, Credit Suisse and the Bundesverband der Deutschen Industrie (BDI) to medium-sized companies that stand out for their clear vision, innovative approaches, sustainable leadership culture and solid financial management.

“With the Axia Best Managed Companies Award, we honor companies that are managed in an exemplary manner – as an incentive and role model for others,” says Lutz Meyer, partner and head of the SME program at Deloitte. In an extremely demanding, three-stage application process, the areas of strategy, innovative strength, corporate culture and finance are analyzed.

The family-owned company Vetter was able to impress the jury with its strategic vision and innovative approaches in all award areas: starting with the systematic strategy process Vetter Excellence 2025, the clear customer focus and innovation management. The jury was also impressed by the anchoring of strategic initiatives in everyday work. For example, Vetter 4.0, with the aim of simulating optimal man-machine processes in the “factory of the future” and then putting them into practice. Or the digitization program Vetter Phoenix, which bundles comprehensive projects such as electronic batch documentation under the title “Working in a digitized pharmaceutical value chain”.

“Vetter has convinced with its first-class corporate management, its high innovative power, a strategy based on a long-term perspective, strong governance structures and sustainable corporate culture, making it a benchmark for excellently managed medium-sized companies and at the same time a symbol for the future of Germany as a business location,” said Lutz about the decision of the expert jury.

For the two managing directors Thomas Otto and Peter Soelkner, winning the award is both confirmation and motivation at the same time: “Time and again in the past we have taken advantage of new opportunities. The award motivates us to continue to do so”.

A glance at the figures also showed the jury that the globally active pharmaceutical service provider is very successful due to its excellent corporate management: In the past ten years, annual sales have more than doubled to around 670 million euros and grown to 5,000 employees .”This success story is based on long-term corporate planning and strategy over decades,” says Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the founding family, sees his work confirmed. „This award is for our Employees“

The Axia Best Managed Companies Award was presented to Vetter in May at a festive, socially distanced, awards ceremony at the pharmaceutical service provider’s headquarters in Ravensburg.

Previous Post

FSD Pharma Gets Go Ahead for Phase IIa COVID-19 Trial

Next Post

Lonza to Host New Webinar – “The Compendia are ready. Are you? A More Sustainable Future for Endotoxin Testing”

Related Posts

FDA Accepts BLA for Recommended
FDA Approvals

FDA Accepts BLA for Recommended Biosimilar to Simponi

22nd July 2025
Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post
Lonza to Host New Webinar

Lonza to Host New Webinar – “The Compendia are ready. Are you? A More Sustainable Future for Endotoxin Testing”

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In